Published in Gene Therapy Weekly, June 29th, 2006
First, the companies have amended and expanded the terms of their license and collaboration agreement. In order to explore new market opportunities for PCA3, Gen-Probe has granted DiagnoCure exclusive rights to develop in vivo products, and co-exclusive rights to develop fluorescence in situ hybridization (FISH) products, using the PCA3 gene. DiagnoCure will pay Gen-Probe royalties on any commercial sales of such products.
In addition, the companies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.